Olive exaggerates value financial savings; Happify Well being experiences DTx curbs nervousness in psoriasis sufferers; and different digital well being briefs


Share post:

Axios’  Erin Brodwin printed a brand new investigation which found healthcare automation startup Olive is exaggerating its capabilities and solely makes use of “tough estimations” to gauge its value financial savings. Based on the report, Olive, which guarantees well being programs value financial savings, is simply monitoring financial savings if a shopper requests it. The report additionally highlighted Olive staff’ issues about how the corporate handles affected person well being info. 

This report comes lower than a 12 months after the corporate closed a whopping $400 million funding spherical, which introduced its valuation to $4 billion. 

Digital therapeutic firm Happify launched outcomes of its real-world psoriasis information evaluation. Researchers discovered that sufferers with psoriasis who accomplished 16 Happify actions inside a minimal of six weeks reported a 27% discount in nervousness signs and a 27% increase in subjective wellbeing.

In the meantime, the examine experiences that people who accomplished lower than 16 actions improved their wellbeing rating by 4.11% and lowered their nervousness rating by 8.15%. 

The analysis was carried out by Happify Well being and isn’t but printed in an educational journal.

Oura, maker of a hoop health-tracking wearable, introduced earlier this week its valuation had reached $2.55 billion. 

Although the corporate did not launch additional particulars, a spokesperson instructed MobiHealthNews it had raised an “oversubscribed” funding spherical. Oura stated the brand new funding will go towards analysis and improvement, customized content material and product innovation.

The startup most not too long ago scooped up $100 million in Sequence C financing in Could 2021. 

Oura revealed its Oura Ring Era 3 in October. The wearable maker stated exercise coronary heart fee monitoring, blood-oxygen sensing and an improved sleep algorithm might be added to the brand new wearable later in 2022. 

Digital pharmacy and telehealth startup Truepill is partnering with COVID-19 testing firm Healing to supply sufferers entry to Truepill’s COVID-19 digital care platform.

When a buyer assessments constructive at considered one of Healing’s testing websites, they will obtain telehealth consults and antiviral drugs by the platform if eligible. Truepill introduced its COVID-19-focused digital care providing in early December

This is not Truepill’s solely digital software aimed toward managing the pandemic. In January, it launched a check protection platform to help payers in growing their very own direct-to-consumer test-purchasing websites, with Truepill fulfilling and delivery orders. In March 2021, the corporate rolled out a set of diagnostics, remedy supply and contact-tracing instruments for the employer market. 

“Entry, pace and scale are important to any COVID-19 response, and that is very true in the case of the distribution of antiviral drugs,” Truepill CEO and cofounder Sid Viswanathan stated in an announcement.

“We’re thrilled to associate with diagnostic testing chief Healing to offer an end-to-end, white-labeled digital care expertise that allows environment friendly, streamlined entry to therapy.”

Supply hyperlink


Please enter your comment!
Please enter your name here


Related articles